As the United States begins the 2025 COVID-19 booster campaign, public interest in alternative treatments like ivermectin has resurfaced. With limited booster access, debates surrounding prescription rules, insurance coverage, and social media-fueled discussions are intensifying. This article explores ivermectin's potential role, challenges, and public perception during the current booster...

In 2025, the United States finds itself at a crossroads in public health policy. Deep federal budget reductions have forced significant CDC news cuts, threatening programs designed to prevent chronic illnesses and monitor infectious diseases. Amid these financial constraints, the re-emergence of ivermectin covid discussions has intensified debates about alternative...